Products

Onxeo designs and develops innovative drugs with unique mechanisms of action in rare and orphan cancers, with a focus on DNA-targeting and resistance to existing treatments.

Orphan Oncology Portfolio

Beleodaq®

AsiDNA™

Livatag®

Earlier in its history, the Company has also developed three drugs based on a proprietary mucoadhesive technology which increases the efficacy or tolerance profile of an active ingredient for its chosen indication. These products have been sold or licensed in 2017.

Other Products